Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

doi:10.2337/dc12-0719

科研成果详情

题名	Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
作者	Hong, Jie 1; Zhang, Yife 1; Lai, Shenghan 2; Lv, Ankang 1; Su, Qing 3; Dong, Yan 3; Zhou, Zhiguang 4; Tang, Weili 4; Zhao, Jajun 5; Cui, Lianqun 5; Zou, Dajin 6; Wang, Dawang 7; Li, Hong 8; Liu, Chao ; Wu, Guoting 9; Shen, Jie 10; Zhu, Dalong 11; Wang, Weiqing 1; Shen, Weifeng 1; Ning, Guang 1
发表期刊	DIABETES CARE 影响因子和分区
语种	英语
原始文献类型	Article
其他关键词	MULTIFACTORIAL INTERVENTION ; MYOCARDIAL-INFARCTION ; ENDOTHELIAL FUNCTION ; GLUCOSE CONTROL ; MORTALITY ; SULFONYLUREAS ; RISK ; ASSOCIATION ; MELLITUS ; AGENTS
摘要	OBJECTIVE-The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS-This study is a multicenter, randomized, doubleblind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36-80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revasculanzation. RESULTS-At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54(95% Cl 0.30-0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS-Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.
资助项目	863 ProjectNational High Technology Research and Development Program of China [2006 AA 02A409]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30971077, 81170784]; Shanghai Shenkang Hospital Development Center [Shdc12007309]; Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Chinese Public Health [1994DP131044]; National Key New Drug Creation and Manufacturing Program [2008ZX09312/019]; Shanghai Committee on Science and Technology [10dz1920802]; Program for Innovative Research Team of Shanghai Municipal Education Commission; Sector Funds of Ministry of Health [201002002]; National Key New Drug Creation and Manufacturing Program of Ministry of Science and Technology [2012ZX09303006-001]
出版者	AMER DIABETES ASSOC
出版地	ALEXANDRIA
ISSN	0149-5992
EISSN	1935-5548
卷号	36 期号:5 页码:1304-1311
DOI	10.2337/dc12-0719
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000319782100039
收录类别	SCIE
发表日期	2013-05
ESI高被引论文	2021-07 ; 2021-09 ; 2021-11 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11
自科自定义期刊分类	T3(A)类
引用统计	被引频次：241[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20531
专题	附属第一医院
通讯作者	Ning, Guang
作者单位	1.Shanghai Jiao Tong Univ Sch Med, Rui Jin Hosp, Shanghai, Peoples R China; 2.Johns Hopkins Univ Sch Med, Baltimore, MD USA; 3.Shanghai Jiao Tong Univ Sch Med, Xinhua Hosp, Shanghai, Peoples R China; 4.Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China; 5.Shandong Univ, Shandong Prov Hosp, Jinan 250100, Peoples R China; 6.Second Mil Med Univ, Chang Hai Hosp, Shanghai, Peoples R China; 7.Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; 8.Sir Run Run Shao Hosp, Hangzhou, Zhejiang, Peoples R China; 9.Tongji Univ, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China; 10.Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; 11.Nanjin Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China
推荐引用方式 GB/T 7714	Hong, Jie,Zhang, Yife,Lai, Shenghan,et al. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease[J]. DIABETES CARE,2013,36(5):1304-1311.
APA	Hong, Jie., Zhang, Yife., Lai, Shenghan., Lv, Ankang., Su, Qing., ... & Ning, Guang. (2013). Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. DIABETES CARE, 36(5), 1304-1311.
MLA	Hong, Jie,et al."Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease".DIABETES CARE 36.5(2013):1304-1311.